Core Viewpoint - The article highlights the innovative advancements of the CybeRay system developed by Shenzhen Dayi Gamma Knife Technology Co., Ltd., emphasizing its dual application for both intracranial and extracranial tumors, which enhances its market competitiveness and investment value [1][4][5]. Company Overview - Shenzhen Dayi Gamma Knife Technology Co., Ltd. has been dedicated to the development and innovation in the medical technology field since its establishment in 1993, focusing on high-end medical equipment, particularly in radiation therapy devices like gamma knives [6]. Product Innovation - The CybeRay system is the first gamma knife to integrate real-time image guidance, marking a significant technological innovation in the field [2]. - CybeRay utilizes multi-beam cobalt-60 gamma rays for precise targeting, achieving sub-millimeter accuracy (<0.5mm) and incorporates cone-beam CT (CBCT) for dynamic correction during treatment [4]. - The treatment process is non-invasive and painless, with a low postoperative complication rate (<0.5%) and a typical treatment duration of 30-60 minutes [4][5]. Clinical Efficacy - Clinical data indicates that the five-year survival rate for patients treated with CybeRay is improved by 10-15% compared to traditional radiation therapy, with recovery times reduced by approximately 30% [5]. Market Positioning - CybeRay is positioned as a significant competitor in the Chinese radiation therapy equipment market, offering a price advantage of approximately 30-40% lower than the Swedish competitor, Elekta's Leksell Gamma Knife, while also providing innovative features [5]. - Despite having less global clinical experience and brand recognition compared to Elekta, CybeRay's rapid clinical deployment and localized services provide substantial growth potential in China and emerging markets [5].